Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18738709 | 0.90 | BRD4 (0.41) | MAPTKDM4EBRD4TNFCYSLTR2 | |
| SCHEMBL20522004 | 0.86 | MAPT (0.39) | MAPTALDH1A1TDP1L3MBTL1NPC1 | |
| SCHEMBL29397620 | 0.83 | MAPT (0.43) | MAPTKDM4EALDH1A1TDP1CRHBP | |
| SCHEMBL17164367 | 0.82 | S1PR4 (0.38) | MAPTALDH1A1L3MBTL1NPC1KMT2A | |
| SCHEMBL18703334 | 0.81 | MAPT (0.43) | MAPTNPC1KMT2AMAPK1MEN1 | |
| SCHEMBL28108700 | 0.81 | PPARA (0.42) | MAPTALDH1A1L3MBTL1NPC1KMT2A | |
| SCHEMBL17164357 | 0.81 | CHRNB4 (0.37) | MAPTCRHBPCRHR2L3MBTL1KMT2A | |
| SCHEMBL21854579 | 0.80 | MAPT (0.37) | MAPTCRHBPCRHR2L3MBTL1KMT2A | |
| SCHEMBL20448215 | 0.80 | MAPT (0.38) | MAPTALDH1A1CRHBPCRHR2L3MBTL1 | |
| SCHEMBL21943236 | 0.79 | BRD4 (0.41) | MAPTALDH1A1TDP1L3MBTL1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| CN-108290903-B | Novel macrocyclic sulfondiimine compounds | 拜耳医药股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108368129-B | Modified macrocyclic compounds | 拜耳医药股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20200347079-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-05 | — | — | US | disclosed |
| EP-3359544-B1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | Bayer Pharma AG (DE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3356373-A1 | NOVEL MACROCYCLIC SULFONDIIMINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9963464-B2 | Macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-08 | — | — | US | disclosed |
| WO-2017060322-A2 | PTEFB-INHIBITOR-ADC | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060167-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060322-A2 | PTEFB-INHIBITOR-ADC | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| EP-3129387-A1 | NOVEL MACROCYCLIC COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029439-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029439-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155197-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155197-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029439-A1 | NOVEL MACROCYCLIC COMPOUNDS | PCNA, CCNI, PKD1 | MAPT 3927/4885KDM4E 4683/4885ALDH1A1 1483/4885 |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MAPT 4662/4885KDM4E 2457/4885ALDH1A1 2433/4885 |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | MAPT 4687/4885KDM4E 2686/4885ALDH1A1 2938/4885 |
| US-20200347079-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | MAPT 4687/4885KDM4E 2686/4885ALDH1A1 2938/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MAPT 4662/4885KDM4E 2457/4885ALDH1A1 2433/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MAPT 4662/4885KDM4E 2457/4885ALDH1A1 2433/4885 |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PPIB, RHEB | MAPT 4662/4885KDM4E 2457/4885ALDH1A1 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.